CA11-19 COLON CANCER MARKER STUDY PUBLISHED AHEAD OF COLORECTAL CANCER AWARENESS MONTH: Online video presents results of a 522 patient study of ColoMarker Sensitivity and Specificity by BF Overholt MD

KNOXVILLE, TN - 2/26/2016 (PRESS RELEASE JET) -- EDP Biotech, a privately-held company providing in-vitro diagnostic test kits for the detection of early colorectal cancer, announces the first multi-center data for CA11-19 detection by ColoMarker – a simple blood test – in CA11-19: a tumor marker for the detection of colorectal cancer , appearing in the March issue of the journal Gastrointestinal Endoscopy. Accompanying the article is an on-line author’s video by Dr. Bergein Overholt, M.D. highlighting the potential benefit of CA11-19 in clinical practice. Clinical performance of ColoMarker was determined utilizing a cohort of 522 consecutively collected serum samples that were obtained under a multi-center IRB protocol. Blood samples were blinded and clinical status was confirmed with colonoscopy prior to testing. Additionally, reproducibility of ColoMarker was evaluated using blinded, duplicate samples run in two U.S. locations and then analyzed.

Data from this multi-center research study demonstrated ColoMarker's 98% sensitivity with 84% specificity in detecting all colorectal cancer. Moreover, the test had 40% sensitivity to pre-cancerous polyps. “If these results are validated by other institutions, approved by the FDA and commercialized, this test will strongly influence the practice of gastroenterology and the management of colorectal cancer patients,” explained 1st author Dr. Bergein Overholt.

EDP Biotech CEO, Eric Mayer stated, “March is Colorectal Cancer Awareness month and highlights the importance of testing for early detection and successful treatment. Colon cancer is the 3rd leading cause of cancer deaths globally, most of which could be prevented by early testing. The lack of patient-friendly testing for CRC is a major contributor to the low compliance rates, currently estimated at less than 60%. We believe that a simple, effective blood test like ColoMarker (CA11-19) will be a valuable diagnostic tool for identification of early-stage disease to win the fight against colorectal cancer.”

About EDP Biotech

Based in Knoxville, Tennessee, EDP Biotech is dedicated to the development and commercialization of innovative cancer diagnostics, including simple, cost-effective, and accurate ELISA-based colon cancer technology. For more information on EDP Biotech, ColoMarker received CE Mark approval in late 2014 and is not currently approved for clinical use in the United States.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. These statements are subject to risks and uncertainties. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Media Contacts:

Company Name: EDP Biotech
Full Name: Lisa Jensen-Long
Phone: 865-229-6232
Email Address:

View Results in Google